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Pharmacotherapy of Smoking Cessation
Kolawole S. Okuyemi, MD, MPH; Jasjit S. Ahluwalia, MD, MPH, MS; Kari J. Harris, PhD, MPH
T obacco use is the number one cause of preventable diseases in the United States. Smok-ing accounts for more than 400 000 deaths yearly and 30% of all cancer deaths. Pri-mary care physicians have access to 70% of smokers, approximately 60% of whom areperceived to be in excellent health. Recent advances in the pharmacotherapy of nico-
tine addiction, including nicotine nasal spray, nicotine inhaler, bupropion hydrochloride, and over-
the-counter transdermal nicotine patches, have increased the treatment options physicians can of-
fer to smokers. Physicians, especially those in primary care specialties, should familiarize themselves
with these products to improve efforts to help their patients stop smoking. This article reviews
scientific data on the efficacy of approved medications, benefits, adverse effects, and appropriate
use of these products. We also discuss nicotine addiction and treatment for special populations,
including women, ethnic minorities, light smokers, and patients with cardiovascular and pulmo-
nary diseases. Arch Fam Med. 2000;9:270-281
Tobacco use is the number one cause of
preventable diseases in the United States.
Smoking accounts for about 435 000
deaths yearly and 30% of all cancer deaths.1
Cigarette smoking is responsible for $50
billion annually in direct medical costs, and
$47 billion in indirect, nonmedical costs.2
Despite widespread efforts to educate the
public on the risks of smoking, the preva-
lence of smoking in the United States re-
mains high. Approximately 46 million
American adults are still current smok-
ers.3 Although smoking prevalence for US
adults has fallen from 42% in 1965 to
25.5% in 1997,4 the proportion of heavy
smokers is higher today than 20 years ago.5
One of the goals of Healthy People
2000 is to increase by 75% the propor-
tion of primary care providers who rou-
tinely provide smoking cessation coun-
seling for their patients who smoke.1
Primary care clinicians have access to ap-
proximately 36 million (70%) of the 50
million people who smoke, including 61%
of smokers who considered themselves to
be in “excellent health.”6,7
HEALTH CONSEQUENCES
OF CIGARETTE SMOKING
Cigarette smoking is associated with sig-
nificant morbidity and mortality, and re-
mains a continued significant threat to
public health. For years, studies have docu-
mented that smokers are at increased risk
of developing numerous diseases includ-
ing cardiovascular disease (eg, coronary
artery disease, stroke, hypertension, and
peripheral vascular disease), cancer (eg,
of the lung, stomach, and bladder), res-
piratory disease (eg, chronic bronchitis and
chronic obstructive pulmonary disease),
and gastric ulcers.8 In addition, cigarette
smoking may create an antiestrogen ef-
fect, accelerating early menopause (and
consequently osteoporosis and other con-
ditions related to estrogen deprivation),
cataracts, and wrinkling.9 While mortal-
ity among nonsmokers has remained
stable, death rates among smokers from
lung cancer, coronary heart disease, and
other smoking-related diseases has in-
creased from 26 per 100 000 to 155 per
100 000 population in women and from
187 per 100 000 to 341 per 100 000 among
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men, from 1959 to 1986, respec-
tively.10 Some minority groups, such
as African Americans, bear a dispro-
portionate share of health conse-
quences of smoking, having the
highest overall cancer mortality rates
compared with other racial and eth-
nic groups.11
IMPACT OF SMOKING
CESSATION
Smoking cessation significantly re-
duces most of the increased health
risks that smokers have incurred.
The degree of improvement, how-
ever, depends on the disease pro-
cess involved, the amount of dam-
age produced, and the reversibility
of this damage at the time of cessa-
tion. According to the 1990 US Sur-
geon General’s report, the higher all-
cause mortality risk in smokers
returns to that of never-smokers
within 10 to 15 years of quitting.12
Former smokers reduce their
riskofdevelopingcoronaryheartdis-
ease 50% within 1 year of quitting,
andafter2yearsofquitting smoking,
former smokers have only twice the
risk of having a first myocardial in-
farction as never-smokers.12 After 4
years, this risk becomes equal to that
of never-smokers. Cancer risk varies
with the type of cancer involved. The
risk of lung cancer in former smok-
ers, for example, always remains
higher than that for never-smokers;
however, this riskdecreasesprogres-
sivelyandconsiderablywiththenum-
ber of years of abstinence.8
NICOTINE DEPENDENCE
Cigarette smoking is an addiction,
as powerful in many respects, as co-
caine or opiate dependence.13 Evi-
dence that tobacco use is more likely
to lead to dependence than any other
drug use is supported by the fact that
among those who have ever tried
even a single cigarette, almost one
third develop nicotine depen-
dence.14 Although most smokers
want to quit, they experience well-
characterized barriers and with-
drawal symptoms during their at-
tempts to quit, and they are largely
unsuccessful in quitting. In fact,
spontaneous quit rates without any
cessation intervention range from
2% to 5% in the United States.15
Nicotine acts on nicotinic ace-
tylcholine receptors in both the cen-
tral nervous system and the periph-
eral nervous system. Its psychoactive
effects are facilitated when nicotine
binds to these acetylcholine recep-
tors, producing an enhanced alert-
ness and a mild euphoria.16 How-
ever, exogenous nicotine binds to the
acetylcholine receptors for longer
than endogenous neurotransmit-
ter, thereby producing a secondary
blockade of these receptors. Over
time, the body adapts to this chronic
secondary antagonism and up-
regulates its central nervous sys-
tem acetylcholine receptors. This is
the physical basis for nicotine tol-
erance. The increased number of
nicotine receptors makes the nor-
mal amount of acetylcholine re-
leased into the synapse insufficient
to maintain the previous mood, and
the biological basis for the physical
dependence is established.
TRENDS IN SMOKING
CESSATION
Quitting smoking is exceedingly dif-
ficult. Surveys show 74% of smok-
ers report a desire to quit smoking
and 70% of smokers have made pre-
vious attempts to quit smoking, yet
success in quitting remains low.5 The
difficulty in quitting that most smok-
ers encounter reflects both a habit
and a physiological addiction. In ad-
dition, cessation involves discon-
tinuing a dependency that smokers
acquired at a vulnerable period in
their lives. Cessation prevalence, or
the quit ratio, defined as the pro-
portion of ever-smokers who are
former smokers (former/ever), has
increased since 1965 from 24% to
50% in 1993.3 Although a sex dif-
ference in smoking cessation ex-
ists, with a quit ratio of 52% for men
and 47% for women, the greater ten-
dency of men to switch from ciga-
rettes to other tobacco products may
account for this difference.3
GUIDELINES FOR SMOKING
CESSATION
In 1996, the Agency for Health Care
Policy and Research (AHCPR) pub-
lished its Smoking Cessation Clini-
cal Practice Guideline.17 The Agency
recommended a 5-step approach,
also known as the 5A’s, to be used
by primary care physicians: Ask—
systematically identify all tobacco us-
ers at every visit, incorporate smok-
ing status as fifth vital sign; Advise—
strongly urge all smokers to quit;
Assess—determine patient’s willing-
ness to make a quit attempt; As-
sist—if patient is willing to make a
quit attempt, help set a quit date, and
encourage nicotine replacement
therapy (NRT) except in special cir-
cumstances; and Arrange—sched-
ule follow-up contact. The recom-
mendation by the AHCPR that NRT
(specifically nicotine gum and trans-
dermal patches) be offered to all
smokers wishing to quit was made
since these were the only drugs ap-
proved for smoking cessation when
the guidelines were developed. How-
ever, a number of other treatment
options, including other NRT and
nonnicotine products, have be-
come available since the release of
the guidelines. The AHCPR guide-
lines are currently being updated and
will be released in mid-2000.
NONPHARMACOLOGICAL
TREATMENT
Although the focus of this article is
pharmacotherapy, a brief review of
other available interventions is pro-
vided to put pharmacotherapy in
perspective. Behavioral interven-
tions are beneficial to the long-
term success of smoking cessation.
Studies have shown that brief (5
minutes or less) advice on quitting
given by physicians to smokers dur-
ing an office visit have resulted in
higher quit rates compared with no
advice.18 In a review of 20 studies
conducted in primary care settings,
Law and Tang19 reported that 2% of
all smokers who received brief phy-
sician advice quit smoking as a di-
rect consequence of it, compared
with 0.1% in smokers who re-
ceived no advice. With additional en-
couragement and support (fol-
low-up letters, telephone calls,
demonstration of spirometry, and
additional visits), quit rates in-
creased to 5%. In that same review,
supportive group sessions for smok-
ers produced similar quit rates as no
advice. While these results suggest
that more intensive interventions
achieve higher quit rates, time con-
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straints experienced by primary care
physicians during office visits20 and
reluctance of many patients to en-
ter intensive programs21 make brief
interventions the more feasible ap-
proach. Readers interested in other
nonpharmacological treatments
should consult other sources for
more detailed reviews.22-24 The low
quit rates associated with unaided
and nonpharmacological quit at-
tempts demands that pharmacologi-
cal treatment be offered to all smok-
ers planning to quit unless there is
a medical contraindication.
PHARMACOLOGICAL
TREATMENT
In 1984, the Food and Drug Admin-
istration (FDA) approved the first
pharmacological agent, nicotine po-
lacrilex gum, for smoking cessa-
tion. It was the only NRT product
available until the introduction in
1992 of transdermal nicotine patch,
the nicotine nasal spray in 1996,
bupropion hydrochloride in 1997,
and the nicotine inhaler in 1998
(Table 1).
Nicotine Replacement Therapy
Since nicotine dependence is a sig-
nificant element of most patients’
smoking behavior, one strategy for
aiding cessation is to pharmacologi-
cally replace nicotine. Smokers can
then engage in behavioral therapy to
decondition their conditioned trig-
gers without experiencing with-
drawal symptoms during absti-
nence. In general, indications and
contraindications for use of all NRT
products are similar. Although the
product insert labels for all NRT
products advise caution in their use
for patients with cardiovascular dis-
eases, studies have shown that these
products cause fewer cardiovascu-
lar effects than nicotine delivered by
tobacco smoke, and are generally
safe for the vast majority of smok-
ers.26 Nicotine replacement prod-
ucts that are FDA approved in-
clude nicotine polacrilex gum,
transdermal nicotine patches, nico-
tine nasal spray, and nicotine in-
haler. Only the first 2 products are
available without prescription.
Nicotine Polacrilex Gum. In 1984,
nicotine polacrilex gum (Nico-
rette, SmithKline Beecham Con-
sumer Healthcare, Pittsburgh, Pa)
became available in the United States
as a prescription-only medication.
Approval for nonprescription sale
was given in 1995 for 2-mg and 4-mg
doses. A box of 48 pieces costs ap-
proximately $30 (Table 2). The
nicotine is buffered in sodium bi-
carbonate, which facilitates absorp-
tion through the buccal mucosa.
Patients generally absorb 50% of
the nicotine in each piece of gum,
providing a bolus of nicotine that
reaches peak venous plasma con-
centrations within 30 minutes. The
venous level of nicotine then slowly
tapers in a pattern resembling, but
significantly slower and less potent
than, that from cigarette smoke. To
benefit from the gum, patients must
Table 1. Drugs Approved for Smoking Cessation*
Drug Usual Dosage Advantages Disadvantages Contraindications
Nicotine polacrilex
(nicotine gum)
Start with 2 mg, use 4 mg if
not successful with 2 mg;
chew 1 gum every 1-2 h
(maximum 30 pieces/d of
2-mg gum or 15 pieces/d
of 40-mg gum); usual length
of treatment is 1-3 mo
Convenient, flexible dosing;
faster delivery of nicotine
than the patch
No food or drink 15 min
before use; frequent
dosing; jaw pain, mouth
soreness, dyspepsia,
hiccups
Dental problems; TMJ syndrome;
use in pregnancy† (category C)
if nonpharmacological
measures fail and if benefits
outweigh risks; avoid use
1 mo post-MI, serious
arrhythmias, or unstable
angina, unless benefits
outweigh risks
Transdermal
nicotine patch
(Nicoderm,
Habitrol,
Nicotrol)
Nicoderm, Habitrol: 21 mg/24 h
for 6-8 wk, then 14 mg/24 h
for 2-4 wk, then 7 mg/24 h
for 2-4 wk; Nicotrol: 15
mg/16 h for 6 wk
Easy to use; daily application;
OTC availability; overnight
use may reduce early
morning cravings; few side
effects
Skin irritation; less flexible
dosing; slow delivery of
nicotine; wearing at
night may cause sleep
problems
Pregnancy (category D) and
cardiovascular warnings
same as for gum
Nicotine nasal spray
Nicotrol NS
(nasal spray)
Use 1-2 doses/h (minimum,
8 doses/d; maximum,
40 doses/d); usual length
of treatment is 3 mo; taper
over 4-6 wk
Flexible dosing; fastest delivery
of nicotine among all
products; reduces cravings
within a few minutes
Frequent dosing; nose and
eye irritation; cough
Pregnancy (category D) and
cardiovascular warnings
same as for gum
Nicotine inhaler
(Nicotrol Inhaler)
10-mg cartridge, but only 4 mg
absorbed; 6-16 cartridges/d;
treat for 3 mo, taper over
6-12 wk
Flexible dosing mimics
hand-to-mouth behavior;
few side effects
Mouth and throat irritation;
frequent dosing
necessary
Pregnancy (category D) and
cardiovascular warnings
same as for gum
Bupropion
(hydrochloride)
SR (Zyban)
150 mg orally once daily for 3 d,
then twice daily for 7-12 wk
Nonnicotine; tablet form; easy
to use; may be used with NRT
Insomnia, dry mouth,
headache, tremors
Pregnancy (category B); seizure
disorder; concurrent use of
Wellbutrin (former trade name)
or an MAO inhibitor; bulimia or
anorexia nervosa
*OTC indicates over the counter; NRT, nicotine replacement therapy; TMJ, temporomandibular joint; MI, myocardial infarction; SR, sustained release; and MAO,
monoamine oxidase.
†Pregnancy risk definitions25 are as follows: A, controlled studies in women fail to demonstrate a risk to the fetus; B, animal studies have either not
demonstrated a fetal risk or have shown an adverse effect not confirmed in controlled studies in women; C, studies in women and animals not available or animal
studies have revealed adverse effects on the fetus but there are no controlled studies in women; and D, there is no positive evidence of human fetal risk, but
benefits from use may be acceptable for a serious disease if safer drugs are unavailable or ineffective.
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chew at least 10 pieces of the gum
per day to absorb about half of the
daily dose of nicotine that they
would otherwise receive from ciga-
rettes. Patients who smoke fewer
than 15 cigarettes per day should use
the 2-mg dose while the 4-mg dose
should be reserved for those who
smoke more. The gum should be
chewed slowly until a “peppery”
taste appears in the mouth, and then
“parked” between the gum and the
cheek until the taste fades. Intermit-
tent chewing and “parking” should
continue for 30 minutes.
The gum may be difficult to use
correctly since it requires special
chewing techniques, and a high fre-
quency of use. Adverse effects from
the gum include jaw fatigue and
soreness and gastrointestinal up-
set, such as gaseous distention, hic-
cups, and nausea.27 The gum is con-
traindicated in patients with gastric
ulcers, and is difficult to use for
patients with dentures.28 Abruptly
stopping polacrilex gum use may
precipitate nicotine withdrawal
symptoms, especially when used be-
yond the recommended 3 months.29
Up to 20% of smokers who success-
fully quit taking the gum use it for
more than 1 year.30 Perhaps second-
ary to its demanding use require-
ments, nicotine gum has been shown
to be more efficacious when used in
specialized clinics than when used
in general medicine practices. In a
meta-analysis of randomized con-
trolled trials, the success rates in spe-
cialized cessation clinics were sig-
nificantly higher with nicotine gum
than with placebo gum at 6 months
(27% vs 18%) and 12 months (23%
vs 13%).31 In contrast, success rates
in general medical practices were no
different with the gum and placebo
(11.7%) at 6 months.32 Higher quit
rates in specialized smoking cessa-
tion clinics may be a result of more
in-depth counseling, better trained
counselors, and possibly smokers
with higher motivation to quit.
Transdermal Nicotine Patches.
Three major brands of transdermal
nicotine patches are currently avail-
able in the United States: Habitrol
(Novartis Consumer Health, Sum-
mit, NJ), Nicoderm CQ (SmithKline
Beecham Consumer Healthcare), and
Nicotrol (McNeil Consumer Prod-
ucts Co, Fort Washington, Pa). Only
the first product requires a prescrip-
tion (Table 1). Patch brands differ in
the rate control mechanisms, start-
ing dose, and weaning regimen.
Patches are sold in 1- to 2-week boxes
at a cost of approximately $30 per
week (Table 2) and initial therapy of
some of the products includes a cas-
sette tape and a self-help booklet. The
Habitrol and Nicoderm CQ patches
are available as 21-mg (6-8 weeks),
14-mg (2-4 weeks), and 7-mg (2-4
weeks) regimens. The overall regi-
men for using these 2 patch brands
is consistent: after approximately 1 to
2 months, patients switch to progres-
sively lower-dose patches until they
are effectively weaned off of the patch.
Patients who smoke at least 10 ciga-
rettes per day can begin with the high-
est dose patch. The Nicotrol patch is
a single-dose patch of 15 mg, and is
intended for daytime use only as a 16-
hour patch (ie, removal before going
to sleep). Treatment is recom-
mended for 6 weeks. The transder-
mal nicotine patch is applied to the
skin daily and nicotine is gradually ab-
sorbed throughout the day. Each
patch delivers 0.9 mg/h of nicotine,
and delivery reaches its daily peak af-
ter approximately 6 hours.16 Cumu-
latively, the nicotine reaches thera-
peutic peak levels (about 13-17 ng/
mL) after 2 to 3 days, when the risk
for smoking relapse is greatest. Se-
rum levels decline 1 to 2 hours after
removing the patch.
Continuous controlled release
of nicotine through a transdermal
nicotine patch resolves some of the
problems associated with nicotine
gum, such as difficulty with use and
side effects. Also, the potential for
addiction to the medication is much
lower by daily self-administration of
nicotine replacement with the patch
than hourly replacement with the
gum.30,33 The most common side ef-
fects of the transdermal nicotine
patches include a mild skin reac-
tion with pruritis and edema. Less
commonly, sleep disturbance has
been reported with the 24-hour
patches. The transdermal patches are
contraindicated for patients with sys-
temic eczema, unstable angina, preg-
nancy, and within 1 month of a myo-
cardial infarction. A number of
studies have shown the success of
the patch under controlled and real-
world settings,34,35 including inner-
city minority populations.36 Effi-
cacy of the nicotine patch is reported
to be about 20% to 30% at 6 months,
which is approximately double the
cessation rate for placebo.37 One im-
portant question that remains un-
answered is how much behavioral
therapy is needed to maximize the
therapeutic effect of the transder-
Table 2. Cost of Drugs Approved for Smoking Cessation
Drug (Manufacturer) Dosage Quantity* Cost, $†
Nicorette (SmithKline Beecham
Consumer Healthcare)
2 mg 48s 28.50
108s 49.11
4 mg 48s 32.08
108s 55.26
Nicoderm CQ (SmithKline Beecham
Consumer Healthcare)
7 mg/24 h
7s 28.50
14 mg/24 h
14s 49.11
21 mg/24 h
Habitrol (Novartis Consumer Health) 7 mg/24 h 30s 120.52
14 mg/24 h 30s 127.22
21 mg/24 h 30s 138.87
Nicotrol (McNeil Consumer Products Co) 15 mg/16 h 14s starter plus 2 refills 43.06
15 mg/16 h 7s refill 24.71
14s refill 43.06
Nicotrol NS (nasal spray)
(McNeil Consumer Products Co)
0.5 mg/inhalation 10 mL 40.80
Nicotrol Inhaler
(McNeil Consumer Products Co)
10 mg 42s 40.80
Zyban (Glaxo Wellcome Inc) 150 mg 60s 83.74
30s 49.47
*Given as number of pieces of gum, patches, or cartridges.
†Average wholesale prices from the 1999 Drug Topics Red Book (Medical Economics Co,
Montvale, NJ).
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mal nicotine patch. Two meta-
analyses published in 1994 have at-
tempted to address this issue.35,37 The
analyses concluded that intensive
follow-up was more efficacious but
the results were not statistically sig-
nificant.
Availability of the transdermal
patches as nonprescription prod-
ucts improves access to their use,
which theoretically would increase
their public health effectiveness.
Some studies have reported similar
quit rates in double-blind, placebo-
controlled trials in nonprescrip-
tion setting when compared with the
prescription setting.38,39 However,
patients enrolled in the nonprescrip-
tion arm of these studies were al-
ready motivated to quit smoking,
and may not be representative of
most smokers.
Nicotine Nasal Spray. Nicotine na-
sal spray (Nicotrol NS, McNeil Con-
sumer Products Co) is a relatively
new (FDA approved in 1996) form
of nicotine replacement delivery
system, available only by prescrip-
tion. It is designed to deliver nico-
tine more rapidly than the gum or
patch, but less rapidly than smok-
ing cigarettes.40 Users tend to self-
administer to plasma nicotine con-
centrations that are approximately
50% of those achieved by smok-
ing.41 The rapid delivery and rela-
tively high plasma concentrations
make the nasal spray more suitable
for treating withdrawal symptoms,
and especially beneficial to highly
dependent smokers. When nico-
tine is administered by nasal spray,
peak plasma concentrations are
reached at a rate comparable to that
from cigarette smoking, and thus can
be used for treating acute nicotine
withdrawal symptoms. The nozzle
is inserted into the nostrils similar
to the technique for antihistamine
or steroid nasal sprays. Each spray
(.05 mL) delivers 0.5 mg of nico-
tine, and a dose is a spray in each
nostril. Patients should be started
with 1 to 2 doses per hour, which
may be titrated up to the maximum
dose of 5 mg/h or 40 mg/d for 3
months. Recommended dosing is 1
to 2 doses every hour for 6 to 8
weeks, followed by 4 to 6 weeks of
gradual reduction by halving the
dose, and decreasing the daily fre-
quency. Although use of the spray
may be stopped abruptly by many
patients without withdrawal ef-
fects, some patients may need taper-
ing. Although no tapering strategy
has been shown to be optimal, a
number of tapering strategies can be
used. Such strategies include hav-
ing patients use half a dose (1 spray)
at a time, use spray less frequently,
skip a dose, try to meet a steadily re-
ducing usage target, and setting a
date to stop use of the spray.42
In a randomized, double-
blind, placebo-controlled study,40
32% of patients using active spray
were abstinent at 6 months com-
pared with 12% taking the placebo.
The rates at 1 year after quit dates
were 26% and 10% for active and
placebo sprays, respectively. These
findings suggest that the nicotine na-
sal spray is helpful in aiding smok-
ing cessation. The most commonly
reported side effects of the nicotine
nasal spray include nasal irritation,
runny nose, sneezing, throat irrita-
tion, coughing, and watery eyes.
Patients develop tolerance to these
effects within the first week. Less fre-
quently, heart pounding, nausea,
headache, dizziness, and sweating
have been reported.
Nicotine Inhaler. In 1998, the nico-
tine inhaler (Nicotrol Inhaler,
McNeil Consumer Products Co) be-
came available as a prescription drug
for smoking cessation. It consists of
a mouthpiece and a plastic car-
tridge designed to deliver 4 mg of
nicotine from a porous plug con-
taining 10 mg of nicotine. The car-
tridge also contains 1 mg of men-
thol as an inactive ingredient to
reduce irritation by nicotine. The
cartridge is inserted into the mouth-
piece prior to use. Nicotine inhaler
is different from other inhalers in
that most of the nicotine released
from the inhaler is absorbed in the
mouth, with less than 5% reaching
the lower respiratory tract.43 A ma-
jor difference between the nicotine
inhaler and other NRT products is
that it mimics the hand-to-mouth
routine similar to cigarette smok-
ing. It may therefore reduce fears as-
sociated with abrupt cessation of the
hand-to-mouth ritual.
In a double-blind, placebo-
controlled trial, individuals using ac-
tive inhalers had continuous absti-
nence rates of 29% and 24%
compared with 14% and 10% with
placebo at 6 weeks and 3 months
postquit date, respectively.44 Other
studies have reported similar find-
ings.45 The average daily dose in
clinical trials was more than 6 car-
tridges for patients who were able to
quit smoking successfully. Patients
should therefore be encouraged to
use at least 6 cartridges per day for
the first 3 to 6 weeks of treatment.
Patients should be allowed to self-
titrate dosage based on severity of
withdrawal signs and symptoms.
Treatment should be continued at
the selected dose for 6 to 12 weeks
in patients who have successfully
quit smoking, followed by tapering
over 3 months. A common taper-
ing strategy used in some trials45 was
to reduce usage by 25% monthly for
3 months. Each puff releases ap-
proximately 16 µg at room tempera-
ture, and each inhaler is designed to
produce approximately 300 puffs.46
An intensive inhalation regimen
(about 80 deep inhalations over 20
minutes) is required to approxi-
mate the amount of nicotine deliv-
ered by smoking 1 cigarette. The
same cartridge can be used up to 5
times before replacing with a new
one. The device should be stored at
room temperature as it may lose sig-
nificant bioavailability at tempera-
tures below 10°C. The mouthpiece
is reusable and should be cleaned
regularly. Adverse effects are gen-
erally mild consisting of throat irri-
tation and cough.
Nonnicotine Drugs
Several nonnicotine products have
been tested for smoking cessation, but
only one has been approved by the
FDA. Initially developed and mar-
keted as an antidepressant under the
trade name Wellbutrin, the sustained-
release form was approved in 1997
as an aid for smoking cessation un-
der a new the trade name, Zyban
(Glaxo Wellcome Inc, Research Tri-
angle Park, NC). Bupropion is an
aminoketone, chemically unrelated
to other known antidepressants. It
has both doperminergic and adren-
ergic actions.47 Although the mecha-
nism by which bupropion enhances
ability of smokers to quit smoking is
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not known, it is presumed to in-
volve both doperminergic and
adrenergic mechanisms.48 Bupro-
pion is an alternative for smokers
who either cannot tolerate NRT or
prefer nonnicotine treatment. In a
randomized, double-blind, placebo-
controlled trial,49 27% of patients who
received the active drug were absti-
nent at 6 months, compared with
16% of patients taking placebo. An
earlier study50 also reported similar
results. The recommended dose is
150 mg orally once daily for 3 days,
then 150 mg twice daily (at least 8
hours apart) for 7 to 12 weeks. Al-
though2brandproductsareavailable
forbupropion,ZybanandWellbutrin,
we recommend that Zyban be pre-
scribedas“donotsubstitute”because
itspackagecomeswiththeZybanAd-
vantagePlan,whichincludesself-help
brochuresandaworkbookandaccess
toapersonalizedsupportprogramfor
smoking cessation. Unlike NRT, pa-
tients should set their quit date 1 to
2 weeks after initiating therapy with
bupropiontoallowsteadystateserum
levels tobeachieved.Cigarette smok-
ing does not significantly affect the
pharmacokineticsofbuproprion.47Ad-
verse effects are generally mild, con-
sisting of insomnia and dry mouth.
The lattereffectmaybeminimizedby
encouraging patients to drink small
amountsofwateratfrequentintervals,
andinsomniacanbereducedbyavoid-
ing bedtime doses. Initial concerns
about increased risk of seizures have
notbeenconfirmed.47 Recentstudies49
with 300 mg/d or less of sustained-
release bupropion hydrochloride for
smokingcessationhavefoundtherisk
ofseizurestobesimilar tothatofother
antidepressants.Thedrugispregnancy
categoryB,andcontraindicatedinpa-
tients with a history of seizures, an-
orexia or bulimia, head trauma, or
heavy alcohol use.
Combination Drug Therapy
Although all the drugs discussed
above have only been approved as
single pharmacological agents, com-
bination treatments may be appro-
priate for smokers who are unable
to quit with monotherapy.
Combined Use of NRT Products.
Given its acute delivery and, there-
fore, usefulness for acute cravings,
some physicians began using polac-
rilex gum in conjunction with the
transdermal nicotine patches. In a
double-blind, placebo-controlled
trial published in 1995, Kornitzer et
al51 randomly assigned 374 smok-
ers (who smoked at least 10 ciga-
rettes a day) to 3 groups: placebo
gum plus placebo patch, active patch
plus placebo gum, and active patch
plus active gum. They reported that
the addition of nicotine gum to the
patch significantly increased quit
rates from 23% to 34% at 12 weeks
and from 15% to 28% at 24 weeks.
Also, a review of 4 studies that docu-
mented statistical significance52 con-
cluded that for heavy smokers, com-
bined use of 5 to 7 pieces per day of
polacrilex gum with the 16- or 24-
hour transdermal patch signifi-
cantly reduces withdrawal symp-
toms and increases initial cessation
rates more than use of either prod-
uct alone. Side effects were not sig-
nificantly increased by combined use
of nicotine patch and gum. A re-
cent study53 also reported higher quit
rates when the patch is combined
with the nasal spray than with the
patch alone (51% vs 35% at 6 weeks
and 37% vs 25% at 3 months for
the combination and patch only,
respectively). Combination treat-
ments should be considered for
smokers with significant craving or
withdrawal despite adequate doses
of single agents and should be con-
tinued for 3 to 6 months.
Combined Use of Transdermal
Nicotine Patch and Bupropion. In
a recent double-blind, placebo-
controlled study54 comparing sus-
tained-release bupropion, a nico-
tine patch, and both for smoking
cessation in 732 smokers, absti-
nence rates at 12 months were 35.5%
in the combination (bupropion plus
nicotine patch) group compared
with 30.3% for bupropion alone,
16.4% for nicotine patch alone, and
15.6% for the placebo patch and pill
group. They concluded that absti-
nence rates were significantly higher
with bupropion in combination with
nicotine patch than with the patch
alone. However, the difference in ab-
stinence rates between the combi-
nation treatment and bupropion
alone was not statistically signifi-
cant. These findings suggest that bu-
propion may be used in combina-
tion with the nicotine patch in
patients without contraindications
to either drugs when deemed nec-
essary. Patients should be started on
bupropion hydrochloride at 150
mg/d for 3 days, then 150 mg twice
daily for 1 to 2 weeks prior to quit
date. Transdermal nicotine patch
therapy should then be added start-
ing on the quit date. We recom-
mend that treatment be continued
for 3 to 6 months.
SPECIAL POPULATIONS
Minorities
Tobacco use varies within and
among racial and ethnic minority
groups in the United States.55 Mem-
bers of racial and ethnic minorities
populations bear a disproportion-
ate share of adverse health conse-
quences of tobacco use, such as can-
cer, cardiovascular diseases, and
preterm births.11,56 Paradoxically, the
1998 Surgeon General’s report noted
that ethnic and racial minorities
are less likely than the general popu-
lation to participate in smoking
cessation groups and to receive ces-
sation advice from health care pro-
viders.55 Compared with whites, Af-
rican Americans smoke fewer
cigarettes, but are more likely to
smoke mentholated brands and
brands with higher tar and nicotine
content.57 Although African Ameri-
can adults are more likely to have a
greater number of quit attempts than
white Americans in any given year,
these attempts are 34% less success-
ful than they are for whites.3,58 Re-
search in pharmacological interven-
tion for smoking cessation has been
conducted almost exclusively in
white, middle-class populations. A
double-blind, randomized, placebo-
controlled trial of the transdermal
nicotine patch among inner-city Af-
rican Americans36 found that the
patch significantly improves quit
rates in this population. The re-
sults from a National Cancer Insti-
tute–funded clinical trial on the ef-
ficacy of bupropion among African
Americans will not be available for
another year. Another study59 in His-
panic smokers found that the trans-
dermal nicotine patch resulted in
nearly doubling of quit rates com-
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pared with placebo. Due to paucity
of data on pharmacological inter-
ventions among minority popula-
tions, the AHCPR recommended
that clinicians who see minority pa-
tients should offer treatments proven
to be effective for the general popu-
lation. Until more conclusive data
become available, physicians should
follow the AHCPR recommenda-
tions that “whenever possible, smok-
ing cessation treatment should be
modified or tailored to be appropri-
ate for ethnic or racial populations
with whom they are used.”17 Nev-
ertheless, clinicians should be aware
of the limitations of such generali-
zation.
Women and Pregnancy
Although the number of male smok-
ers continues to outnumber female
smokers (26% for men vs 21% for
women in 1997), mortality from
lung cancer in women continues to
rise.60 In fact, lung cancer, mostly
due to smoking, is the leading cause
of cancer deaths in women.60 Cur-
rent data suggest that women are
quitting at same rate as men.61 Fac-
tors that undermine cessation in
women include depression, social
support, and weight gain.62 It is not
clear whether women experience
more withdrawal symptoms than
men during abstinence.61 Some data
have suggested that men do better
with NRT, but these results have not
been replicated.63 Smoking during
pregnancy has well-documented
consequences on maternal and fe-
tal health, including low birth
weight, spontaneous abortion, and
preterm births.64 Many pregnant
women find it difficult to quit on
their own.65 Quitting cigarette smok-
ing during early pregnancy reduces
the risk of low birth weight.12 Even
women who quit smoking as late as
the 30th week of gestation have in-
fants with higher birth weights than
those who continue to smoke.41 Cur-
rent evidence suggests that behav-
ioral therapy for pregnant smokers
is effective66 and should be encour-
aged before pharmacological ap-
proaches are used. All the NRT prod-
ucts are pregnancy category D except
the gum, which is category C. The
level of nicotine to which the fetus
is exposed with the patch or gum is
lower than that from cigarettes. Re-
views on use of the gum and patch
during pregnancy suggest that their
use should still be considered. The
risk-benefit ratio appears favorable
if efforts to quit without medi-
cation has failed.67 Use of nicotine
inhaler or nicotine nasal spray dur-
ing pregnancy has not been exam-
ined. Bupropion carries pregnancy
category B label, and could be used
if nonpharmacological efforts have
failed. The risks and benefits of any
medication used for smoking cessa-
tion during pregnancy should be ex-
plained to mother.
Smokers With
Cardiovascular Diseases
Smokers are clearly at higher risk of
dying from smoking-related cardio-
vascular diseases such as coronary
artery disease, stroke, congestive
heart failure, and other heart dis-
eases.68 Also important is the fact that
the risk of cardiovascular disease de-
creases markedly within 1 year of
stopping smoking and approxi-
mates the risk in never-smokers 5
years after cessation. Quitting smok-
ing has a greater impact on morbid-
ity and mortality than changing diet,
weight, or exercise.12 On the other
hand, studies have shown that NRT
is safe in patients with stable car-
diovascular diseases.69 There is no
evidence that bupropion use in-
creases the cardiovascular risk of
smokers. In view of the favorable
risk-benefit ratio in patients with
stable cardiovascular diseases, phar-
macotherapy should be offered to
this population of smokers. Physi-
cians should adopt a more aggres-
sive approach in this population, in-
cluding the use of combination
pharmacological therapy as these pa-
tients are likely to be more nicotine
dependent.
Smokers With
Pulmonary Diseases
Cigarette smoking is an important
risk factor for pulmonary diseases,
being responsible for 85 000 deaths
per year from respiratory diseases
such as chronic obstructive pulmo-
nary disease and pneumonia.70 Stop-
ping smoking halts the smoking-
induced accelerated decline in lung
function seen with chronic obstruc-
tive pulmonary disease.12 Docu-
mented changes in pulmonary func-
tion may be used as a motivational
factor for smoking cessation in these
patients. As with patients with car-
diovascular diseases, those who con-
tinue to smoke despite having pul-
monary diseases are likely to be
highly nicotine dependent71; hence,
treatment with pharmacological
agents is very important in this
population of smokers.
Light Smokers
Current data suggest that 5% to 10%
of smokers consume 5 or fewer ciga-
rettes a day,72 although the propor-
tion is much higher among African
Americans and Hispanic popula-
tions.73 These smokers in general are
not addicted to nicotine, and may ab-
stain from smoking for days with-
out significant withdrawal ef-
fects.74 Light smokers are invariably
excluded in virtually all pharmaco-
logical smoking cessation trials. The
quit rates of the pharmacological
agents discussed herein were de-
rived from studies in regular smok-
ers who smoke 10 or more ciga-
rettes a day. Consequently, there is
insufficient data about effective
smoking cessation interventions for
light smokers. However, light smok-
ers should equally be strongly en-
couraged to quit, as there is no safe
level of smoking. It is logical that
drug therapy should only be con-
sidered after nonpharmacological
measures have failed.
ADJUNCTIVE MATERIALS
Primary care physicians should con-
sider offering adjunctive materials to
supplement educational and sup-
portive counseling. All pharmaco-
logical agents discussed herein were
approved to be used in conjunc-
tion with a behavioral smoking ces-
sation program. Virtually all these
products provide some form of self-
help kits in their initial or starter
packages. Some also provide smok-
ing cessation videotapes and infor-
mation about where smokers may
call in to receive counseling. The
American Lung Association has pro-
duced a number of materials, 2 pub-
lications of which are specifically
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produced for patients wishing to quit
on their own: a 64-page cessation
guide, Freedom From Smoking in 20
Days, and a 28-page maintenance
booklet, A Lifetime of Freedom From
Smoking. The National Cancer In-
stitute has also produced many pub-
lications, including Clearing the Air,
all of which are available free. A list-
ing of these and other resources that
may be helpful to both physicians
and their patients is provided at the
end of this article.
GENERAL CONSIDERATIONS
Relapse
Physicians should be aware that re-
lapse is quite common among smok-
ers both during and after cessation
treatment. In fact, studies have
shown that it takes an average of 4
to 5 quit attempts before eventual
success at cessation.13 Patients
should therefore be encouraged to
try to quit again as soon as possible
after a failed attempt. In assessing pa-
tients who relapse, physicians should
address patient and treatment fac-
tors that may have contributed to the
failed attempt. Patient factors in-
clude lack of motivation (provide
motivational counseling such as dis-
cussing the pros and cons of smok-
ing); environmental stressors such
as death or illness within the fam-
ily, loss of job, being around or
living with other smokers (provide
relevant counseling or refer as ap-
propriate); and presence of comor-
bidities, especially alcohol abuse and
depression as up to 20% of heavy
smokers have current alcohol prob-
lems and 40% have a history of de-
pression.75-77 Treatment consider-
ations include adequacy of dosage
(whether dose prescribed was ad-
equate or patient used medication as
prescribed), cost (whether prescrip-
tion was affordable or was paid for
by insurance plan), and drug ad-
verse effects that affected treatment
compliance. If the patient agrees to
try again, a new quit date should be
set. If dosage of the medication used
in prior attempt was adequate, and
relapse was due to uncontrolled
withdrawal, the patient should be
considered for combination treat-
ment. We recommend a combina-
tion of one long-acting agent (trans-
dermal nicotine patch or bupropion)
plus a shorter-acting, quick-onset
agent (nicotine polacrilex gum, nico-
tine inhaler, or nicotine nasal spray).
Treatment should be continued
for 3 to 6 months followed by 6 to
12 weeks of tapering of the short-
acting nicotine product if neces-
sary. Patients should be given ad-
equate instructions in proper use of
the medication and the necessary fol-
low-up provided. Follow-up con-
tact is vital and should be made
within 1 week of the quit date be-
cause relapse rates are highest dur-
ing the first few days after cessa-
tion.78,79 Follow-up could be in the
office, by telephone, or by mail, and
can be made by the physician or
other trained office staff. We recom-
mend that patients who relapse
after 2 or 3 attempts despite ad-
equate treatment and careful con-
siderations of the factors discussed
herein should be referred to a smok-
ing cessation specialist.
Addictive Potential
Some studies have reported that 5%
to 20% of patients prescribed the po-
lacrilex nicotine gum for smoking
cessation continue to use the gum
for 1 year or more.72,80 Although
abrupt cessation of use of the gum
can produce withdrawal symptoms
similar to but milder than that from
cigarettes,81 the use of the gum can
be safely eliminated by gradual re-
duction. Long-term use may repre-
sent patient’s desire to extend du-
ration of therapy for fear of returning
to smoking.82 Abrupt cessation of the
transdermal nicotine patch does not
appear to be associated with with-
drawal symptoms.83 Nicotine nasal
spray seems to have a higher poten-
tial for long-term use than the gum
as evidenced by findings from clini-
cal trials that up to 43% of those ab-
stinent at 1 year were still using the
spray at 1 year.41 Gradual dose re-
duction (over 1-3 months) should
be implemented for those using the
spray beyond 3 months. Long-term
use did not appear to be a problem
for the nicotine inhaler as all pa-
tients were able to discontinue
inhaler use within 6 months in
clinical trials. No problems with
long-term use have been reported
with bupropion.
CHOICE OF
PHARMACOLOGICAL
AGENTS
Given the many options of pharma-
cotherapy available for smoking ces-
sation today, physicians are likely to
be asked which of these products
their patients should use. This situ-
ation is further compounded in man-
aged care settings where health plans
may recommend certain agents over
others. Factors that should be con-
sidered in drug therapy include effi-
cacy, cost, ease of use, adverse effect
profile, and patient characteristics.
There are limited data on the com-
parative efficacy of the 5 approved
agents (Table 3) —nicotine polac-
rilex gum, transdermal nicotine
patch, nicotine nasal spray, nicotine
inhaler, and bupropion. In a recent
study, Hajek et al91 conducted a com-
parative trial of nicotine polacrilex
gum, transdermal nicotine patch,
nicotine nasal spray, and nicotine in-
haler. These researchers found that
the 4 NRTs did not differ in their ef-
fects on withdrawal discomfort, urges
to smoke, or rates of abstinence with
12-week continuous abstinence rates
of 20%, 21%, 24%, and 24% for gum,
patch, spray, and inhaler groups, re-
spectively. In the same study, com-
pliance was high for the patch (82%),
low for the gum (38%), and very low
for the spray (15%) and the inhaler
(11%). The spray was underused be-
cause of adverse effects, and the in-
haler was rated as more embarrass-
ing to use than other products. These
findings suggest that although the 4
products are equally efficacious, com-
pliance and adverse event profile ap-
pear to favor the patch. However, that
the higher compliance and lower ad-
verse event rates did not lead to bet-
ter quit rates in the patch group sug-
gest that various NRTs may have
different appeal and efficacy in dif-
ferent populations of smokers. In an-
other study, Jorenby et al54 com-
pared the efficacy of bupropion and
nicotine patch as single agents and as
combined therapy. The abstinence
rates were 18.8%, 21.3%, 34.8%, and
38.8% at 6 months, and 15.6%,
16.4%, 30.3%, and 35.5% at 12
months for placebo, nicotine patch
only, bupropion only, and com-
bined bupropion and nicotine patch,
respectively. Although this study sug-
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gests superior efficacy for bupro-
pion over the patch, it is premature
to draw conclusions or make recom-
mendations based on a single study.
The comparative efficacy and toler-
ability of all 5 products have not been
reported in the literature. It is good
judgment to consider using prod-
ucts with better compliance and fewer
adverse events such as the transder-
mal patch before other NRTs. It is im-
portant to note, however, that cer-
tain patient characteristics such as
preferences, comorbidities, experi-
ence in prior quit attempts, and de-
gree of nicotine dependence may war-
rant use of the spray and inhaler as
initial therapy. Bupropion may be
used as initial therapy either alone or
(for more nicotine-dependent pa-
tients) in combination with NRTs. Al-
though there are anecdotal reports
that some health plans are recom-
mending bupropion as first-line
therapy over the NRTs, such recom-
mendations are not supported by cur-
rent research. We recommend that
physicians consider using an algo-
rithm (Figure) to assist them in iden-
tification and triaging of therapy for
smokers.
CONCLUSIONS
The recent increase in approved
pharmacological options for smok-
ing cessation provides primary care
physicians with a wide range of treat-
ment approaches. When used cor-
rectly, all currently approved prod-
ucts appear to be equally efficacious,
approximately doubling quit rates
compared with placebo.92 It is there-
fore logical that patient’s prefer-
ence, comorbidities, and adverse ef-
fect profile of individual agents
should guide treatment choice. In-
creased access created by nonpre-
scription availability of some NRTs
has been credited with substantial in-
crease in smokers quitting in the
United States.93 Some studies re-
ported finding no difference in ab-
stinence rates with nonprescrip-
tion use of nicotine patch compared
with its use in prescription setting,
suggesting physician advice had no
effect in the use of these products.
However, since the major role of
physician advice is to motivate
smokers to quit,94-96 failure to dem-
onstrate a significant effect in the
studies may be because these smok-
ers were already motivated. Given
the fact that primary care physi-
cians have contact with 70% of
smokers in a given year, they are in
a unique position to influence a sig-
nificant proportion of smokers. Phy-
sicians should be aware of the spe-
cial needs of certain populations of
smokers, including women, ethnic
minorities, light smokers, and pa-
tients with cardiovascular and pul-
monary diseases.
Given the proven effective-
ness of smoking cessation interven-
tions and their potential to reduce
smoking-related morbidity and mor-
tality, failure to identify, advise, and
offer pharmacological agents to
smokers may soon be judged as de-
viation from standard of care. Phy-
sicians may consider the efficacy of
smoking cessation intervention as
generally low compared with that of
treatment with antibiotics or anti-
hypertensives. However, smoking
cessation should be put into proper
perspective. If physicians achieve a
5% quit rate in 70% of the 50 mil-
lion (35 million) smokers seen by
primary care physicians yearly, this
will result in 1.73 million smokers
quitting each year. As physicians en-
deavor to educate and empower their
patients with regard to their health,
this significant contributor to per-
sonal and social morbidity cannot
be ignored. Of all preventive care
efforts, smoking cessation promo-
tion has the potential to achieve
the most dramatic reduction in
morbidity and mortality, and
improvement in public health.
The ultimate disease prevention
strategy would be to prevent initia-
tion of smoking. In spite of wide-
spread knowledge of health con-
sequences, 3000 Americans, mostly
teenagers and children, start smok-
ing each day. Although we ad-
dressed the important role of phar-
macotherapy of smoking cessation,
it should be recognized that a sus-
tained reduction in smoking preva-
lence will require a comprehensive
population-based approach. Such an
approach should include efforts
aimed at reducing social desirabil-
ity of smoking, limiting access to
cigarettes, and increasing availabil-
ity as well as utilization of effective
cessation intervention. Finally, as ef-
forts to promote smoking cessation
interventions are sustained, we ex-
pect to see an increase in the provi-
sion of cessation interventions, in-
creased quit rates, and an ultimate
reduction in smoking-related mor-
bidity and mortality.
Accepted for publication November 16,
1999.
Table 3. Studies Reporting 6-Month and 1-Year Quit Rates
of Approved Pharmacological Agents*
Study
Quit Rate at 6 mo, % Quit Rate at 1 y, %
Active
Treatment Placebo P
Active
Treatment Placebo P
Nicotine gum
Schneider et al84 48.0 20.0 ,.05 30.0 20.0 ,.05
Lam et al32 27.0 18.0 ,.05 23.0 13.0 ,.05
Nicotine patch
Hurt et al85 29.2 15.0 ,.05 27.5 14.2 ,.05
Sachs et al86 33.6 12.1 ,.05 24.8 9.4 ,.05
Tonnesen et al87 19.3 2.8 ,.05 12.4 2.8 ,.05
Nicotine nasal spray
Blondal et al88 29 18 .05 25 17 .09
Hjalmarson et al89 44 19 ,.05 34 18 ,.05
Schneider et al90 25 10 ,.05 18 8 ,.05
Nicotine inhaler
Leischow et al45 21.0 6.0 ,.05 11.0 5.0 .14
Tonnesen et al46 17.2 7.8 ,.05 15.2 5.0 ,.05
Bupropion hydrochloride
Hurt et al49 27 16 ,.05 23.1 12.4 ,.05
Jorenby et al54 34.8 18.8 ,.001 30.3 15.6 ,.001
*These rates are derived from noncomparative studies, so quit rates can only be compared within rows
but not across rows.
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SUGGESTED HELPS
1. The American Lung Association (ALA) offers sev-
eral manuals, including Freedom From Smoking in
20 Days (how to quit), A Lifetime of Freedom From
Smoking (avoiding relapse), and Freedom From
Smoking for You and Your Baby (a quit program
for pregnant women). A contribution of $7 is re-
quested for the manuals, which can be obtained
through local ALA chapters, or by writing the Ameri-
can Lung Association, 1740 Broadway, New York,
NY 10019. Telephone (800) LUNG-USA. Internet:
http://www.lungsusa.org.
2. The American Heart Association offers free publica-
tions including Calling It Quits, Smoking and Heart
Disease, Smoking and Strokes: Two Things You Can
Live Without, and Children and Smoking: A Message
toParents.Contacta local chapter,orwrite theAmeri-
can Heart Association, 7272 Greenville Ave, Dallas,
TX 75231. Telephone (800) AHA-USA1 (242-8721).
Internet: http://www.americanheart.org.
3. The American Cancer Society offers a wide variety
of materials including antismoking programs
aimed at young people. Consult a local chapter to
obtain materials, or write the American Cancer
Society, 1599 Clifton Rd NE, Atlanta, GA 30329.
Telephone: (800) ACS-2345. Internet: http://
www.cancer.org.
4. The National Cancer Institute offers free publica-
tions Quit for Good and Clearing the Air. Call (800)
4-CANCER (422-6237). Internet: http://www
.nci.nih.gov.
5. National Heart, Lung, and Blood Institute, Building
31, Room 4A21, Bethesda, MD 20892. Telephone
(301) 496-4236.
6. NicotineAnonymous,POBox591777,SanFrancisco,
CA 94159-1777. Telephone (415) 750-0328.
7. American Academy of Family Physicians (AAFP) of-
fers the “AAFP Stop Smoking Kit” for use in office
practice, with audiotapes for physicians and office
staff, a charting system, and self-help materials for
patients. The cost is $60 for AAFP members and $90
for nonmembers. Call (800) 274-2237, ext 5500.
8. Kits that come alongside the display or with the pur-
chase of nicotine replacement products and bupro-
pion, including such helps as a toll-free counseling
telephone number, a smoking cessation guide,
and/or smoking cessation videotapes.
Clinical Pearl
Spironolactone for Heart Failure
In a large randomized trial of patients with severe heart fail-
ure (left ventricular ejection fracture of no more than 0.35),
at a mean follow-up of 2 years, patients in the group that
received 25 mg of spironolactone had a relative risk of death
of 0.70 (95% CI, 0.60-0.82; P,.001) compared with the
group that received placebo. The patients who received spi-
ronolactone also had fewer hospital admissions and better
cardiac function status. Gynecomastia or breast pain was re-
ported by 10% of the men who received spironolactone.
(N Engl J Med. 1999;341:709-717.)
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